New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide

ONCOLOGY

Volumn 14, Issue 12 SUPPL. 13, 2000, Pages 25-28

  Hwu, Wen Jen ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; CASE REPORT; FEMALE; HUMAN; MALE; MELANOMA; METASTASIS; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW;

ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DACARBAZINE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; THALIDOMIDE;

EID: 0034572793     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Balch CM, Soong S-J, Murad TM, et al: A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases. J Clin Oncol 1:126, 1983.
2. Klimek VM, Wolchok JD, Chapman PB, et al: Systemic chemotherapy. Clin Plast Surg 27:451, 2000.
3. Chapman PB, Einhorn LH, Meyer ML, et al: Phase III inulticenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999.
4. Rusthoven J, Quirt IC, Iscoe NA, et al: Randomized, double blind, placebo-controlled trials comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14:2083-2090, 1996.
5. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alpha-2b. J Clin Oncol 17:968-975, 1999.
6. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 18:158-166, 2000.
7. Summers Y, Middleton MR, Calvert H, et al: Effect of temozolomide on central nervous system relapse in patients with advanced melanoma (abstract 2048). Proc Am Soc Clin Oncol 18:531a, 1999.
8. Brock CS, Newlands ES, Wedge SR, et al: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363-4367, 1998.